MK-5684

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Castration-Resistant Prostatic CancerEnd-Stage Kidney DiseaseHealthy ParticipantsKidney Failure, ChronicMetastasisProstatic NeoplasmsRenal Failure, ChronicRenal Failure, End-Stage

Phase 1

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

CompletedNCT06554639

Merck Sharp & Dohme LLCProstatic Neoplasms

Start: 2024-07-11End: 2024-08-29Updated: 2024-10-15

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

CompletedNCT06814132

Merck Sharp & Dohme LLCEnd-Stage Kidney Disease, Healthy Participants, Kidney Failure, Chronic +2

Start: 2025-04-07End: 2025-10-14Updated: 2025-10-23

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

RecruitingNCT06863272

Merck Sharp & Dohme LLCCastration-Resistant Prostatic Cancer, Metastasis

Start: 2025-07-03End: 2031-04-01Target: 360Updated: 2026-04-02